Summary
232.77
4.60
(2.02%)
06/05/2026
Johnson & Johnson (JNJ)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years |
| 2.02 | 4.14 | 3.78 | -2.30 | 16.55 | 55.27 | 62.54 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan!
Fundamental Ratings
| Category | Rating |
| Main Rating | B+ |
| Recommended Rating | Neutral |
| DCF | Buy |
| ROE | Strong Buy |
| ROA | Strong Buy |
| Debt/Equity | Sell |
| P/E | Sell |
| P/B | Strong Sell |
Earnings
| Trading Data | ||
| Close | 232.77 | |
| Open | 230.00 | |
| High | 235.22 | |
| Low | 229.00 | |
| Volume | 8,034,922 | |
| Change | 4.60 | |
| Change % | 2.02 | |
| Avg Volume (20 Days) | 7,698,637 | |
| Volume/Avg Volume (20 Days) Ratio | 1.04 | |
| 52 Week Range | 145.41 - 250.27 | |
| Price vs 52 Week High | -6.99% | |
| Price vs 52 Week Low | 60.08% | |
| Range | 1.20 | |
| Gap Up/Down | 1.33 | |
Profitibility | ||
| Market Capitalization (Mln) | 451,213 | |
| Revenue per share | 39.4081 | |
| Net Income per share | 8.6045 | |
| Dividend Yield | 0.0225 | |
| Dividend Share | 524.00% | |
Valuations | ||
| Enterprise Value | 0.00% | |
| PE Ratio | 27.0521 | |
| PB Ratio | 0.0000 | |
| PTB Ratio | 0.0000 | |
Liquidity | ||
| Debt/Equity Ratio | 0.0000 | |
| Net Debt/EBIDTA Ratio | 0.0000 | |
| Current Ratio | 0.0000 | |
Enterprise Value and Cash Flow | ||
| EV/Sales Ratio | 0.0000 | |
| EV/EBIDTA Ratio | 0.0000 | |
| EV/Free Cash Flow Ratio | 0.0000 | |
06/06 10:15 EST - fool.com
Why Johnson & Johnson May Be the Closest Thing Investors Can Find to a Bulletproof Dividend Stock
When Tylenol pills were tampered with and tainted in 1982, Johnson & Johnson managed the setback in stride. More recently, the healthcare giant has been navigating legal issues related to talcum powder, which it once manufactured.
Why Johnson & Johnson May Be the Closest Thing Investors Can Find to a Bulletproof Dividend Stock
When Tylenol pills were tampered with and tainted in 1982, Johnson & Johnson managed the setback in stride. More recently, the healthcare giant has been navigating legal issues related to talcum powder, which it once manufactured.
06/05 18:19 EST - seekingalpha.com
Dividend Champion, Contender, And Challenger Highlights: Week Of June 7
A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates.
Dividend Champion, Contender, And Challenger Highlights: Week Of June 7
A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates.
06/05 10:10 EST - zacks.com
Can JNJ Sustain Growth Amid Patent, Legal and China Risks?
J&J faces Stelara erosion, China MedTech pressure and talc litigation, but targets $100B revenues and faster growth in 2026.
Can JNJ Sustain Growth Amid Patent, Legal and China Risks?
J&J faces Stelara erosion, China MedTech pressure and talc litigation, but targets $100B revenues and faster growth in 2026.
06/05 09:18 EST - 247wallst.com
Five Boring Dividend Aristocrats That Quietly Pay $36,000 a Year on $850,000 Without a Single Yield Trap
Replacing $36,000 a year in income is roughly equivalent to generating the cash flow from a maximum Social Security benefit for a single retiree, or about $3,000 a month before taxes. A 66-year-old with $850,000 in a taxable brokerage account can build that income stream using five Dividend...
Five Boring Dividend Aristocrats That Quietly Pay $36,000 a Year on $850,000 Without a Single Yield Trap
Replacing $36,000 a year in income is roughly equivalent to generating the cash flow from a maximum Social Security benefit for a single retiree, or about $3,000 a month before taxes. A 66-year-old with $850,000 in a taxable brokerage account can build that income stream using five Dividend...
06/05 08:45 EST - fool.com
Healthcare ETFs: PJP Focuses on Pharmaceuticals, While XBI Zeroes in on Biotech
Compare risk profiles, dividend strategies, and portfolio concentration as these two healthcare ETFs take different paths to long-term returns.
Healthcare ETFs: PJP Focuses on Pharmaceuticals, While XBI Zeroes in on Biotech
Compare risk profiles, dividend strategies, and portfolio concentration as these two healthcare ETFs take different paths to long-term returns.
06/05 08:19 EST - 247wallst.com
Dividend Aristocrats on Sale: 5 Decades-Long Raisers Trading Below Target
Five Dividend Aristocrats with streaks ranging from 54 to 70 consecutive years of payout hikes are currently trading below Wall Street's consensus price targets, and four of the five just beat their most recent EPS estimates.
Dividend Aristocrats on Sale: 5 Decades-Long Raisers Trading Below Target
Five Dividend Aristocrats with streaks ranging from 54 to 70 consecutive years of payout hikes are currently trading below Wall Street's consensus price targets, and four of the five just beat their most recent EPS estimates.
06/04 18:45 EST - zacks.com
Johnson & Johnson (JNJ) Exceeds Market Returns: Some Facts to Consider
In the latest trading session, Johnson & Johnson (JNJ) closed at $228.17, marking a +2.21% move from the previous day.
Johnson & Johnson (JNJ) Exceeds Market Returns: Some Facts to Consider
In the latest trading session, Johnson & Johnson (JNJ) closed at $228.17, marking a +2.21% move from the previous day.
06/04 10:00 EST - 247wallst.com
How to Maximize Dividend Income in Retirement Before RMDs Change the Math
At the 24% federal bracket, a portfolio throwing off $40,000 in high-yield dividend income hands roughly $9,600 to the IRS every year when those shares sit in a taxable account treated as ordinary income. For investors in the gap years between retirement and RMD age 73, that drag compounds quietly...
How to Maximize Dividend Income in Retirement Before RMDs Change the Math
At the 24% federal bracket, a portfolio throwing off $40,000 in high-yield dividend income hands roughly $9,600 to the IRS every year when those shares sit in a taxable account treated as ordinary income. For investors in the gap years between retirement and RMD age 73, that drag compounds quietly...
06/04 06:51 EST - 247wallst.com
Can Pure Dividend Stocks Replace a $110,000 Dual-Income Household Income? Here’s What It Would Take
A combined household income of $110,000 is close to the national norm for a two-earner household. For a 56-year-old couple hoping to retire at age 60 and fund their lifestyle entirely through dividend income, that annual amount becomes the income target their portfolio must replace. The basic...
Can Pure Dividend Stocks Replace a $110,000 Dual-Income Household Income? Here’s What It Would Take
A combined household income of $110,000 is close to the national norm for a two-earner household. For a 56-year-old couple hoping to retire at age 60 and fund their lifestyle entirely through dividend income, that annual amount becomes the income target their portfolio must replace. The basic...
06/04 06:34 EST - prnewswire.com
CereVasc, Inc. Announces Over-Subscribed $85 Million Series C Financing to Advance its Novel eShunt® System for the Treatment of Normal Pressure Hydrocephalus
Financing led by Piper Sandler Merchant Banking, with participation from new investors Johnson & Johnson Innovation – JJDC, Inc., Johnson & Johnson's corporate venture capital arm, and Medtronic Participation by existing investors, including Bain Capital Life Sciences and Perceptive Xontogeny...
CereVasc, Inc. Announces Over-Subscribed $85 Million Series C Financing to Advance its Novel eShunt® System for the Treatment of Normal Pressure Hydrocephalus
Financing led by Piper Sandler Merchant Banking, with participation from new investors Johnson & Johnson Innovation – JJDC, Inc., Johnson & Johnson's corporate venture capital arm, and Medtronic Participation by existing investors, including Bain Capital Life Sciences and Perceptive Xontogeny...
06/03 12:51 EST - zacks.com
Are You Looking for a High-Growth Dividend Stock?
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?
Are You Looking for a High-Growth Dividend Stock?
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?
06/03 10:00 EST - zacks.com
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
06/03 07:45 EST - 247wallst.com
This Is What a $1 Million Dividend Portfolio Pays After Taxes
At the 24% federal bracket, a $1 million dividend portfolio generating roughly $45,000 in annual income can hand the IRS between $6,750 and $10,800 every year, depending on how much of that income is qualified versus ordinary. Inside a Roth IRA, that same income lands in your account untouched....
This Is What a $1 Million Dividend Portfolio Pays After Taxes
At the 24% federal bracket, a $1 million dividend portfolio generating roughly $45,000 in annual income can hand the IRS between $6,750 and $10,800 every year, depending on how much of that income is qualified versus ordinary. Inside a Roth IRA, that same income lands in your account untouched....
06/03 01:00 EST - gurufocus.com
Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study
Johnson and Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2
Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study
Johnson and Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2
06/03 01:00 EST - gurufocus.com
Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease
Johnson and Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease
Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease
Johnson and Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease
06/02 18:24 EST - cnbc.com
Jim Cramer says look to buy these 5 stocks outside the AI trade for diversification
CNBC's Jim Cramer said investors should consider adding exposure to out-of-favor sectors if investors begin rotating away from high-flying technology stocks. He highlighted JPMorgan, Johnson & Johnson, Kimberly-Clark, McDonald's, Yum!
Jim Cramer says look to buy these 5 stocks outside the AI trade for diversification
CNBC's Jim Cramer said investors should consider adding exposure to out-of-favor sectors if investors begin rotating away from high-flying technology stocks. He highlighted JPMorgan, Johnson & Johnson, Kimberly-Clark, McDonald's, Yum!
06/02 14:30 EST - fool.com
Johnson & Johnson Hopes to Dethrone AbbVie's Biggest Growth Driver. Here's Why Investors Shouldn't Panic
AbbVie's shareholders can sleep easy.
Johnson & Johnson Hopes to Dethrone AbbVie's Biggest Growth Driver. Here's Why Investors Shouldn't Panic
AbbVie's shareholders can sleep easy.
Market News
×
Loading news…